Accelmed Partners is a lower middle-market private equity firm focused on acquiring and investing in U.S. commercial-stage HealthTech companies. For more than a decade, we have leveraged our deep HealthTech industry experience, operational and financial expertise, and strong relationships to help management teams at companies across the medical device, tools, diagnostics, digital health and tech-enabled services sectors position their businesses for future growth and success. Our ideal partners share our values of integrity, transparency and tenacity, directed toward leveraging technology to improve patient outcomes, reduce costs and increase efficiency throughout the healthcare system. We currently manage over $630 million of equity capital and are actively investing out of our second private equity fund, Accelmed Partners II.
Location: United States, Florida, Miami
Employees: 1-10
Founded date: 2009
Investment Type: Private Equity Firm
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 05.08.2022 | Diagnostic... | diagnosticrobotics.com | $45M | United Sta... |
Mentions in press and media 23
| Date | Title | Description |
| 19.06.2025 | Corvia Medical: $55 Million Raised For Treating Heart Failure | Corvia Medical, a company dedicated to transforming the treatment of heart failure, announced the closing of a $55 million funding round from its existing investment syndicate, which includes Third Rock Ventures, General Catalyst Partners, ... |
| 18.06.2025 | Corvia Medical Secures $55 Million to Revolutionize Heart Failure Treatment | In a significant move for heart failure treatment, Corvia Medical, Inc. has successfully closed a $55 million funding round. This funding comes from a group of existing investors, including Third Rock Ventures, General Catalyst Partners, Ac... |
| 17.06.2025 | Corvia Medical Raises $55M in Funding | Corvia Medical, Inc, a Tewksbury, MA-based company dedicated to improve the treatment of heart failure, raised $55M in funding. Backers included Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two investors. T... |
| 17.06.2025 | Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt | Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the succe... |
| 02.06.2025 | Acclaro Medical's $23 Million Leap: A New Era in Aesthetic Technology | In the world of medical technology, innovation is the lifeblood that fuels progress. Acclaro Medical, a Smithfield, Rhode Island-based company, has just secured a significant $23 million in Series B funding. This investment, led by Accelmed... |
| 29.05.2025 | Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology | Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market Growth SMITHFIELD, R.I., May 29, 2025 /PRNewswire/ -- Acclaro Medical, a pioneering medical technol... |
| 24.01.2025 | GT Medical Technologies: Pioneering a New Era in Brain Tumor Treatment with $37 Million Series D Funding | In the ever-evolving landscape of medical technology, GT Medical Technologies stands out like a lighthouse in a storm. This Tempe, Arizona-based company has recently secured $37 million in Series D funding, a financial boost that promises t... |
| 22.01.2025 | GT Medical Technologies: $37 Million (Series D) Raised For Improving Lives Of Patients With Brain Tumors | GT Medical Technologies – a medical device company that aims to improve patients’ lives with brain tumors – announced that the company has completed the $37 million first close of a Series D funding round. The funding was led by Evidity Hea... |
| 21.12.2024 | Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards | Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial TEWKSBURY, Mass., Dec. 21, 2024 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it ... |
| 26.11.2024 | TailorMed Secures $40M to Improve Medication Access and Affordability | What You Should Know: –TailorMed, a leading innovator in healthcare technology, announced a $40 million financing round combining equity and debt. This investment positions the company to advance its bold vision of transforming medication a... |
Show more